Allterum's development of its 4A10 monoclonal antibody targeting ALL approved to receive support through the National Cancer Institute Experimental Therapeutics Program

Allterum Therapeutics, Inc. (Allterum) has been approved to receive support from the National Cancer Institute (NCI) Experimental Therapeutics (NExT) Program. NCI is part of the National Institutes of Health. The approval will support key product development activities for Allterum's 4A10...